Table 2.

Patient/tumor characteristics and retinoid use details in young-aged uveal melanoma cases.

Case	Age/Gender	Tumor/Patient history/Baseline visual acuity	Ocular/facial symptoms and history	Type of Retinoid usea	Duration of Retinoid use	Using retinoid at dx
1	16 F	Ciliochoroidal melanoma, T3bN0M0 rightb 20/25 OD, 20/20 OS	Blurry vision, ocular headache	Topical	10 mos	Yes
2	35 M	Ciliochoroidal melanoma, T3bN0M0 left, class 1B History of cone-rod dystrophy, active smoker 20/200 OU	Persistent light sensitivity, floaters, visual disturbance	Oral	3 mos	No
3	31 F	Choroidal macular-peripapillary melanoma, T1aN0M0 rightb Family history OM; pregnant at time of diagnosis 20/30 OD, 20/20 OS	Visual disturbance, wavy lines, central vision changes Facial rash on retinoid	Topical	6 years	Yes
4	27 F	Choroidal melanoma, T2aN0M0 left, class 1A 20/20 OD, 20/25 OS	Tingling sensation in eyes Facial skin sensitivity on retinoid	Topical - tazarotene	10 years	Yes
5	32 M	Choroidal melanoma, T1aN0M0 left, multigene panel low risk Possible secondary Chernobyl exposure; past smoker 20/20 OU	Persistent dryness of eyes Temporary lip dryness on retinoid	Oral	6–12 mos	No
6	44 M	Ciliary body melanoma, T2bN0M0 left, class 1A, PRAME negative OD 20/25, 20/30 OS	Ocular nevus other eye Facial patches, dry lips on retinoid	Oral + Topical	3 years	No

^aRetinoid use was isotretinoin (oral) and tretinoin (topical) unless otherwise noted.

^bPt chose to forgo biopsy.